home / stock / pgnx / pgnx news

PGNX News and Press, Progenics Pharmaceuticals Inc. From 06/25/19

Stock Information
Company Name: Progenics Pharmaceuticals Inc.
Stock Symbol: PGNX
Market: NASDAQ
Website: progenics.com
Menu
PGNX PGNX Quote PGNX Short PGNX News PGNX Articles PGNX Message Board
Get PGNX Alerts

News, Short Squeeze, Breakout and More Instantly...
PGNX - Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics' PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from studies highlighting the PSMA-targeted imag...
PGNX - Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders

ALPHARETTA, Ga. , June 25, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful spe...

PGNX - Independent Readers Using Progenics' PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from a study evaluating the diagnostic performan...

PGNX - Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan's Latest Inaccurate Claims

Board has Positioned Progenics to Maximize Value as a Result of Proactive and Deliberate Strategy Velan’s Baseless Criticisms about the Development of AZEDRA and 1095 Reveal a Fundamental Lack of Understanding of Radiopharmaceuticals Shareholders Should Question Velanȁ...
PGNX - Velan Releases Detailed Presentation on Progenics Pharmaceuticals

ALPHARETTA, Ga. , June 20, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful spe...

PGNX - Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors

NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announ...

PGNX - Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims

ALPHARETTA, Ga. , June 20, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful special...
PGNX - Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan

NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight, and follow cancer, today announced that EXINI, a wholly owned subsidiary of Progenics, has entered into ...

PGNX - Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements

ALPHARETTA, Ga. , June 17, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialt...

PGNX - Progenics to Mail Letter to Shareholders

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, is mailing a lette...
Previous 10 Next 10